Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_4
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 4Post-market surveillance
3(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Other(1)

Detailed Status

Completed4
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (50.0%)
Phase 43 (50.0%)

Trials by Status

completed467%
recruiting117%
unknown117%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_4

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

NCT07531108
recruitingphase_4

Glycemic Variability of Combination Therapies in T2DM

NCT07442006
unknownphase_4

The Effects of Empagliflozin on Arterial Wall Characteristics

NCT03639545
completedphase_1

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

NCT02266472
completedphase_1

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

NCT02230995
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07531108Phase 4

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

Completed
NCT07442006Phase 4

Glycemic Variability of Combination Therapies in T2DM

Recruiting
NCT03639545Phase 4

The Effects of Empagliflozin on Arterial Wall Characteristics

Unknown
NCT02266472Phase 1

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Completed
NCT02230995Phase 1

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Completed
NCT01811953Phase 1

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6